414 related articles for article (PubMed ID: 33657636)
1. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
[TBL] [Abstract][Full Text] [Related]
6. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
7. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
[TBL] [Abstract][Full Text] [Related]
9. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
[TBL] [Abstract][Full Text] [Related]
10. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
Wang DY; Saleem M; Paes BA; Mitchell I; Li A; Lanctôt KL;
Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
[TBL] [Abstract][Full Text] [Related]
11. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab Adherence and Outcomes in Canadian Aboriginal Children.
Hui C; Paes B; Papenburg J; Mitchell I; Li A; Lanctôt KL;
Pediatr Infect Dis J; 2016 Nov; 35(11):1187-1193. PubMed ID: 27331856
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus (RSV) infection in children with medical complexity.
Lim A; Butt ML; Dix J; Elliott L; Paes B
Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab.
Paes B; Li A; Kim D; Lanctot KL; Mitchell I;
Am J Perinatol; 2021 Aug; 38(S 01):e129-e136. PubMed ID: 32232817
[TBL] [Abstract][Full Text] [Related]
15. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
16. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
[TBL] [Abstract][Full Text] [Related]
17. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
Luna MS; Manzoni P; Paes B; Baraldi E; Cossey V; Kugelman A; Chawla R; Dotta A; Rodríguez Fernández R; Resch B; Carbonell-Estrany X
Paediatr Respir Rev; 2020 Feb; 33():35-44. PubMed ID: 31060948
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
20. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]